Drug Profile
Goralatide
Alternative Names: AcSDKP; BIM 32001; BN 52040; SeraspenideLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Ipsen
- Class Oligopeptides; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced damage; Haematological disorders; Transplant rejection
Most Recent Events
- 11 Jun 1997 Preclinical development for Haematological disorders in France (Unknown route)
- 24 Jan 1995 Phase-II clinical trials for Transplant rejection in France (Unknown route)
- 24 Jan 1995 Phase-II clinical trials for Transplant rejection in Germany (Unknown route)